Target intelligence / Profile preview

Nuclear receptor-binding SET domain protein 1 (NSD1)

Target
NSD1
Molecular classification
Enzyme, Histone methyltransferase, Chromatin modifier, Epigenetic regulator
01

Overview

Nuclear receptor-binding SET domain protein 1 (NSD1) is a large, multi-domain histone methyltransferase that catalyzes the mono- and di-methylation of lysine 36 on histone H3 (H3K36), and may also act on histone H4 at lysine 20. Containing a catalytic SET domain, PWWP domains, PHD fingers, and interaction motifs for nuclear receptors, NSD1 is a critical chromatin regulator involved in transcriptional activation and repression. It regulates gene expression during embryonic development and controls growth, and is implicated in multiple diseases when mutated or dysregulated. NSD1 loss-of-function causes Sotos syndrome, a childhood overgrowth disorder, while chromosomal rearrangements involving NSD1 are oncogenic in acute myeloid leukemia and other cancers. NSD1 acts both as a tumor suppressor and oncogene, depending on cellular context, and is an emerging epigenetic target in oncology research.

Other names
Histone-lysine N-methyltransferase, H3 lysine-36 specificLysine N-methyltransferase 3BKMT3BARA267Nuclear receptor SET domain-containing protein 1Androgen receptor coactivator 267 kDa proteinSOTOSSOTOS1
02

Mechanism of action

Drugs targeting NSD1 (if developed) would likely act as histone methyltransferase inhibitors, blocking methylation of H3K36 to influence gene expression and chromatin state.

03

Biological functions

Histone methylation (mono- and di-methylation at H3K36, also activity at H4K20)Transcriptional regulation (co-activator and co-repressor functions)Chromatin remodelingRegulation of gene expression during developmentMaintenance of genomic integrityRegulation of cell growth, DNA repair, and differentiation
04

Disease associations

Cancer (e.g., acute myeloid leukemia, breast cancer, melanoma, neuroblastoma, glioblastoma)Developmental disorders (notably Sotos syndrome)Overgrowth syndromesNeurodevelopmental disease
05

Safety considerations

Targeting NSD1 may pose a risk of disrupting normal development, as it is critical for growth, neurodevelopment, and homeostasis.NSD1 loss-of-function is associated with overgrowth, learning disabilities, and developmental delay (Sotos syndrome).Complete systemic inhibition could increase risk of genomic instability and unintended epigenetic effects.
06

Interacting drugs

No approved small molecule inhibitors or drugs are noted to directly target NSD1. Experimental inhibitors of NSD1 and related methyltransferases are under investigation, but not clinically advanced. No commonly used drugs interact directly with NSD1 per current clinical knowledge.
07

Biomarkers

NSD1 mutations (for Sotos syndrome diagnosis or stratification)NSD1 gene fusions with NUP98 (in acute myeloid leukemia)Loss-of-function or promoter methylation status (as a tumor suppressor marker in certain cancers)

Beyond the preview

Go deeper on Nuclear receptor-binding SET domain protein 1 (NSD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear receptor-binding SET domain protein 1 (NSD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call